Zika vaccines and therapeutics: Landscape analysis and challenges ahead

Annelies Wilder-Smith, Kirsten Vannice, Anna Durbin, Joachim Hombach, Stephen J. Thomas, Irani Thevarjan, Cameron P. Simmons

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background: Various Zika virus (ZIKV) vaccine candidates are currently in development. Nevertheless, unique challenges in clinical development and regulatory pathways may hinder the licensure of high-quality, safe, and effective ZIKV vaccines. 

Discussion: Implementing phase 3 efficacy trials will be difficult given the challenges of the spatio-temporal heterogeneity of ZIKV transmission, the unpredictability of ZIKV epidemics, the broad spectrum of clinical manifestations making a single definite endpoint difficult, a lack of sensitive and specific diagnostic assays, and the need for inclusion of vulnerable target populations. In addition to a vaccine, drugs for primary prophylaxis, post-exposure prophylaxis, or treatment should also be developed to prevent or mitigate the severity of congenital Zika syndrome. 

Conclusion: Establishing the feasibility of immune correlates and/or surrogates are a priority. Given the challenges in conducting phase 3 trials at a time of waning incidence, human challenge trials should be considered to evaluate efficacy. Continued financial support and engagement of industry partners will be essential to the successful development, licensure, and accessibility of Zika vaccines or therapeutics.

Original languageEnglish
Article number84
Number of pages15
JournalBMC Medicine
Volume16
Issue number1
DOIs
Publication statusPublished - 6 Jun 2018

Keywords

  • Anti-virals
  • Clinical endpoints
  • Efficacy trials
  • Flavivirus
  • Human controlled infections
  • Immune correlates
  • Immune surrogates
  • Monoclonal antibodies
  • Prophylaxis
  • Therapeutics
  • Zika
  • Zika diagnostics
  • Zika vaccines

Cite this

Wilder-Smith, A., Vannice, K., Durbin, A., Hombach, J., Thomas, S. J., Thevarjan, I., & Simmons, C. P. (2018). Zika vaccines and therapeutics: Landscape analysis and challenges ahead. BMC Medicine, 16(1), [84]. https://doi.org/10.1186/s12916-018-1067-x
Wilder-Smith, Annelies ; Vannice, Kirsten ; Durbin, Anna ; Hombach, Joachim ; Thomas, Stephen J. ; Thevarjan, Irani ; Simmons, Cameron P. / Zika vaccines and therapeutics : Landscape analysis and challenges ahead. In: BMC Medicine. 2018 ; Vol. 16, No. 1.
@article{a8788a6de5204d768e2dfa285e2320a7,
title = "Zika vaccines and therapeutics: Landscape analysis and challenges ahead",
abstract = "Background: Various Zika virus (ZIKV) vaccine candidates are currently in development. Nevertheless, unique challenges in clinical development and regulatory pathways may hinder the licensure of high-quality, safe, and effective ZIKV vaccines. Discussion: Implementing phase 3 efficacy trials will be difficult given the challenges of the spatio-temporal heterogeneity of ZIKV transmission, the unpredictability of ZIKV epidemics, the broad spectrum of clinical manifestations making a single definite endpoint difficult, a lack of sensitive and specific diagnostic assays, and the need for inclusion of vulnerable target populations. In addition to a vaccine, drugs for primary prophylaxis, post-exposure prophylaxis, or treatment should also be developed to prevent or mitigate the severity of congenital Zika syndrome. Conclusion: Establishing the feasibility of immune correlates and/or surrogates are a priority. Given the challenges in conducting phase 3 trials at a time of waning incidence, human challenge trials should be considered to evaluate efficacy. Continued financial support and engagement of industry partners will be essential to the successful development, licensure, and accessibility of Zika vaccines or therapeutics.",
keywords = "Anti-virals, Clinical endpoints, Efficacy trials, Flavivirus, Human controlled infections, Immune correlates, Immune surrogates, Monoclonal antibodies, Prophylaxis, Therapeutics, Zika, Zika diagnostics, Zika vaccines",
author = "Annelies Wilder-Smith and Kirsten Vannice and Anna Durbin and Joachim Hombach and Thomas, {Stephen J.} and Irani Thevarjan and Simmons, {Cameron P.}",
year = "2018",
month = "6",
day = "6",
doi = "10.1186/s12916-018-1067-x",
language = "English",
volume = "16",
journal = "BMC Medicine",
issn = "1741-7015",
publisher = "Springer-Verlag London Ltd.",
number = "1",

}

Wilder-Smith, A, Vannice, K, Durbin, A, Hombach, J, Thomas, SJ, Thevarjan, I & Simmons, CP 2018, 'Zika vaccines and therapeutics: Landscape analysis and challenges ahead' BMC Medicine, vol. 16, no. 1, 84. https://doi.org/10.1186/s12916-018-1067-x

Zika vaccines and therapeutics : Landscape analysis and challenges ahead. / Wilder-Smith, Annelies; Vannice, Kirsten; Durbin, Anna; Hombach, Joachim; Thomas, Stephen J.; Thevarjan, Irani; Simmons, Cameron P.

In: BMC Medicine, Vol. 16, No. 1, 84, 06.06.2018.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Zika vaccines and therapeutics

T2 - Landscape analysis and challenges ahead

AU - Wilder-Smith, Annelies

AU - Vannice, Kirsten

AU - Durbin, Anna

AU - Hombach, Joachim

AU - Thomas, Stephen J.

AU - Thevarjan, Irani

AU - Simmons, Cameron P.

PY - 2018/6/6

Y1 - 2018/6/6

N2 - Background: Various Zika virus (ZIKV) vaccine candidates are currently in development. Nevertheless, unique challenges in clinical development and regulatory pathways may hinder the licensure of high-quality, safe, and effective ZIKV vaccines. Discussion: Implementing phase 3 efficacy trials will be difficult given the challenges of the spatio-temporal heterogeneity of ZIKV transmission, the unpredictability of ZIKV epidemics, the broad spectrum of clinical manifestations making a single definite endpoint difficult, a lack of sensitive and specific diagnostic assays, and the need for inclusion of vulnerable target populations. In addition to a vaccine, drugs for primary prophylaxis, post-exposure prophylaxis, or treatment should also be developed to prevent or mitigate the severity of congenital Zika syndrome. Conclusion: Establishing the feasibility of immune correlates and/or surrogates are a priority. Given the challenges in conducting phase 3 trials at a time of waning incidence, human challenge trials should be considered to evaluate efficacy. Continued financial support and engagement of industry partners will be essential to the successful development, licensure, and accessibility of Zika vaccines or therapeutics.

AB - Background: Various Zika virus (ZIKV) vaccine candidates are currently in development. Nevertheless, unique challenges in clinical development and regulatory pathways may hinder the licensure of high-quality, safe, and effective ZIKV vaccines. Discussion: Implementing phase 3 efficacy trials will be difficult given the challenges of the spatio-temporal heterogeneity of ZIKV transmission, the unpredictability of ZIKV epidemics, the broad spectrum of clinical manifestations making a single definite endpoint difficult, a lack of sensitive and specific diagnostic assays, and the need for inclusion of vulnerable target populations. In addition to a vaccine, drugs for primary prophylaxis, post-exposure prophylaxis, or treatment should also be developed to prevent or mitigate the severity of congenital Zika syndrome. Conclusion: Establishing the feasibility of immune correlates and/or surrogates are a priority. Given the challenges in conducting phase 3 trials at a time of waning incidence, human challenge trials should be considered to evaluate efficacy. Continued financial support and engagement of industry partners will be essential to the successful development, licensure, and accessibility of Zika vaccines or therapeutics.

KW - Anti-virals

KW - Clinical endpoints

KW - Efficacy trials

KW - Flavivirus

KW - Human controlled infections

KW - Immune correlates

KW - Immune surrogates

KW - Monoclonal antibodies

KW - Prophylaxis

KW - Therapeutics

KW - Zika

KW - Zika diagnostics

KW - Zika vaccines

UR - http://www.scopus.com/inward/record.url?scp=85048075716&partnerID=8YFLogxK

U2 - 10.1186/s12916-018-1067-x

DO - 10.1186/s12916-018-1067-x

M3 - Article

VL - 16

JO - BMC Medicine

JF - BMC Medicine

SN - 1741-7015

IS - 1

M1 - 84

ER -

Wilder-Smith A, Vannice K, Durbin A, Hombach J, Thomas SJ, Thevarjan I et al. Zika vaccines and therapeutics: Landscape analysis and challenges ahead. BMC Medicine. 2018 Jun 6;16(1). 84. https://doi.org/10.1186/s12916-018-1067-x